These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 26020125

  • 1. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
    Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T.
    J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125
    [Abstract] [Full Text] [Related]

  • 2. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [Abstract] [Full Text] [Related]

  • 3. Ceritinib in ALK-rearranged non-small-cell lung cancer.
    Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA.
    N Engl J Med; 2014 Mar 27; 370(13):1189-97. PubMed ID: 24670165
    [Abstract] [Full Text] [Related]

  • 4. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
    Tan DS, Thomas M, Kim DW, Szpakowski S, Urban P, Mehra R, Chow LQM, Sharma S, Solomon BJ, Felip E, Camidge DR, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw AT.
    Lung Cancer; 2022 Jan 27; 163():7-13. PubMed ID: 34890832
    [Abstract] [Full Text] [Related]

  • 5. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R, Greystoke A, Lal R, Thompson J, Popat S.
    Lung Cancer; 2017 Sep 27; 111():51-58. PubMed ID: 28838397
    [Abstract] [Full Text] [Related]

  • 6. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
    Hida T, Satouchi M, Nakagawa K, Seto T, Matsumoto S, Kiura K, Nokihara H, Murakami H, Tokushige K, Hatano B, Nishio M.
    Jpn J Clin Oncol; 2017 Jul 01; 47(7):618-624. PubMed ID: 28369553
    [Abstract] [Full Text] [Related]

  • 7. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.
    Lancet Oncol; 2017 Jul 01; 18(7):874-886. PubMed ID: 28602779
    [Abstract] [Full Text] [Related]

  • 8. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
    Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.
    Jpn J Clin Oncol; 2018 Apr 01; 48(4):367-375. PubMed ID: 29474558
    [Abstract] [Full Text] [Related]

  • 9. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES, Barlesi F, Mok T, Ahn MJ, Shen J, Zhang P, Ou SI.
    Future Oncol; 2021 May 01; 17(14):1709-1719. PubMed ID: 33569983
    [Abstract] [Full Text] [Related]

  • 10. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.
    Lancet Oncol; 2016 Dec 01; 17(12):1683-1696. PubMed ID: 27836716
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
    Hida T, Seto T, Horinouchi H, Maemondo M, Takeda M, Hotta K, Hirai F, Kim YH, Matsumoto S, Ito M, Ayukawa K, Tokushige K, Yonemura M, Mitsudomi T, Nishio M.
    Cancer Sci; 2018 Sep 01; 109(9):2863-2872. PubMed ID: 29959809
    [Abstract] [Full Text] [Related]

  • 12. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
    Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A.
    J Hematol Oncol; 2016 Mar 10; 9():23. PubMed ID: 26966027
    [Abstract] [Full Text] [Related]

  • 13. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A.
    J Thorac Oncol; 2017 Sep 10; 12(9):1357-1367. PubMed ID: 28729021
    [Abstract] [Full Text] [Related]

  • 14. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT.
    J Clin Oncol; 2016 Aug 20; 34(24):2866-73. PubMed ID: 27432917
    [Abstract] [Full Text] [Related]

  • 15. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
    Mok TSK, Crino L, Felip E, Salgia R, De Pas T, Tan DSW, Chow LQM.
    Cancer Treat Rev; 2017 Apr 20; 55():181-189. PubMed ID: 28427013
    [Abstract] [Full Text] [Related]

  • 16. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
    Santoro A, Su WC, Navarro A, Simonelli M, Ch Yang J, Ardizzoni A, Barlesi F, Hyoung Kang J, DiDominick S, Abdelhady A, Chen X, Stammberger U, Felip E.
    Lung Cancer; 2022 Apr 20; 166():170-177. PubMed ID: 35298959
    [Abstract] [Full Text] [Related]

  • 17. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Wu YL, Shi Y, Tan DSW, Xiaoqing L, Cheng Y, Zhou J, An TT, Lu Y, Zhu B, Bai C, Passos VQ, Lau YY, Xun L, Zhang L.
    Lung Cancer; 2020 Dec 20; 150():240-246. PubMed ID: 33249379
    [Abstract] [Full Text] [Related]

  • 18. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y.
    Anticancer Res; 2017 Nov 20; 37(11):6477-6480. PubMed ID: 29061835
    [Abstract] [Full Text] [Related]

  • 19. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 20; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

  • 20. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.
    EBioMedicine; 2016 Jan 20; 3():54-66. PubMed ID: 26870817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.